GlobeNewswire

NuVinci® Cycling Goes Sportive with N380x(TM)

Dela

Introducing a new stepless transmission specifically designed for sportive and cargo bicycle models

AMSTERDAM, NETHERLANDS / CEDAR PARK, TEXAS, Aug. 01, 2017 (GLOBE NEWSWIRE) -- NuVinci Cycling, a division of Fallbrook Technologies Inc., extends its product portfolio by introducing its newest NuVinci Optimized(TM) continuously variable planetary transmission (CVP), the N380x, for the trending sportive applications. The N380x will extend the benefits of the NuVinci® stepless technology by making it available to additional bicycle types, use-cases, and riders.

Recently, the market has seen a significant increase in the amount of newly launched bicycle models that are influenced by sportive design approaches but are being used in a non-performance environment. Typically, sportive bike models are used on forest roads or in parks, with a fitness or a commuting purpose and require a suitable, durable, stepless transmission.

"There are quite a few new types of bike models emerging, both in the eBike and traditional bicycle market. Consumers are looking for sportive products to fit into their usual day-to-day commute and new hybrids between city and mountain bikes are meeting those needs. These hybrid models place different demands on their components, therefore we crafted the N380x - specifically designed to meets the needs of the emerging and more sportive models and more importantly, the riders' needs," says Anne Guethoff, Director of Marketing at NuVinci Cycling.

With its ratio range of 380%, and a maximum continuous input torque of 100Nm in certain conditions, the transmission was developed to offer best-in-class performance for sportive and speed pedelec bicycle types, used under full load acceleration. Plus, the 10*135, 12*142, and 12*148 dropout options enable compatibility with B+ tires for better traction. The N380x comes with all common thru axle adapter types, allowing increased frame stiffness and easy maintenance. The anodized housing and laser engraved product branding ensure a high-end appearance over the long-term. To further ensure great material strength and reliable lasting performance, the component selection includes a forged housing and a freewheel with individual spring pawls. To make it even easier for riders to fully focus on the road conditions, the N380x is available with the Harmony(TM) automatic shifting system. Finally, several internal components in the N380x are upgraded from the N380(TM) transmission. These upgrades increase durability and robustness more than any previously produced NuVinci Optimized transmission.

Scott will be the first OEM to launch a model with N380x at EUROBIKE 2017. "Scott is best known for its sportive models. With our newest project, the E-Silence Evo, we wanted to offer our customers an urban eBike with a sportive appeal. The new N380x fits perfectly with the high-end concept of our bike. With its high performance attributes, it allows us to shift steplessly under full motor power. With the modern design, it is the ideal combination for our sportive target group. In addition, by integrating the shifting system into the eBike controls, we are able to offer a clean handlebar and an intuitive control," summarizes Thomas Berger, Product Manager at Scott.

Besides the trend towards more sportive models, the next wave of eBikes is also looking at inner-city transport solutions. Commercial businesses and consumers alike are seeking ways that enable them to easily transport heavier loads over short distances. As a result, the cargo bike segment is growing fast and requires a durable transmission, which allows shifting under higher loads, even at standstill. With the durability and flexibility of the N380x, it perfectly answers those needs. Therefore, cargo bike riders can enjoy stepless shifting, whether they are freewheeling, shifting under heavy load or waiting at a traffic light.

About NuVinci® Cycling

NuVinci Cycling, a division of Fallbrook Technologies Inc., moves people better through its product portfolio of smooth, stepless, automatic and integrated shifting products for bicycles and eBikes. The NuVinci technology incorporated in continuously variable transmissions (CVT) for bicycles has been providing the best rider experiences since 2006. NuVinci Cycling products include the Nfinity(TM) and Harmony(TM) group sets, utilizing the latest versions of the transmissions and controllers. Products from NuVinci Cycling are available globally in over 100 bicycle brands. For more information, visit www.nuvincicycling.com

About Fallbrook Technologies

Fallbrook Technologies is the inventor of the revolutionary NuVinci® continuously variable planetary (CVP) technology, which enables performance and efficiency improvements for machines that use an engine, pump, motor, or geared transmission system - including urban mobility vehicles, cars and trucks, industrial equipment, and many other applications. Fallbrook has a unique collective development model and community through which NuVinci technology licensees share enhancements, which adds to the value of the technology and accelerates product development. This approach enables forward-looking companies, who wish to create visionary new products with NuVinci technology, to move quickly from concept to market commercialization. Fallbrook is based in Cedar Park near Austin, Texas, USA and holds rights to over 800 patents and patent applications worldwide. For more information, visit www.fallbrooktech.com.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/63aad2ff-65ab-4899-b668-bc82b02cd39a

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c7ceae79-f4e4-4af3-9dac-1a34aea67fd4

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/76486d61-6af0-4380-b1e7-22d46289074d

Anne Guethoff, Director of Marketing
NuVinci Cycling | a Division of Fallbrook Technologies
+ 49 160 92290159
Anne.Guethoff@nuvincicycling.com

Trammie Anderson, Director of Corporate Marketing
Fallbrook Technologies Inc.
512-519-5194
trammie.anderson@fallbrooktech.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuVinci Cycling via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum